Chen, Yi-Bin <br/><br/>
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.  [electronic resource] 

 -  Cancer  Jan 2015 
 - 226-33 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.29023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Busulfan--administration & dosage<br/>Central Nervous System Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Cytarabine--administration & dosage<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Female<br/>Hematopoietic Stem Cell Transplantation--methods<br/>Humans<br/>Induction Chemotherapy--methods<br/>Infusions, Intravenous<br/>Lymphoma, Non-Hodgkin--drug therapy<br/>Male<br/>Massachusetts<br/>Middle Aged<br/>Rituximab<br/>Thiotepa--administration & dosage<br/>Transplantation Conditioning--methods<br/>Transplantation, Autologous